Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2016

View Archived Issues

Role of SUMOylated SOD2 in alcoholic liver disease and liver cancer

FDA expands indication for FluLaval influenza vaccine

FDA grants fast track designation to Oragenics' AG-013

IBT receives positive recommendation to continue phase II trial of IBP-9414

FDA lifts partial clinical hold on trials evaluating Aduro Biotech's LADD platform

AbbVie discontinues development program under Halozyme collaboration

Intarcia Therapeutics submits NDA for ITCA-650

Janssen Pharmaceutica patents TARPgamma8 inhibitors

WHO announces global health funding for RTS,S malaria vaccine

Janssen R&D Ireland discloses agents for RSV infection

Actelion Pharmaceuticals describes TPHI1 inhibitors

Rosetta Genomics enters research agreement with Sheba Medical Center

FDA approves Darzalex in combination with standard of care for relapsed multiple myeloma

Roche presents HBsAg and HBV DNA production inhibitors

FDA approves Soliqua for type 2 diabetes

FDA lifts partial clinical hold on head and neck cancer trials of durvalumab

Midatech receives payment under Emergex license contract

Pan-Nox inhibitor for diabetic nephropathy

Novo Nordisk's Xultophy wins FDA approval for type 2 diabetes

Sandoz's epoetin alfa biosimilar for renal anemia

Regulus chemically modified oligonucleotide for Alport syndrome

Novel Zika virus vaccine based on the Zika E glycoprotein

Phase I clinical testing of the hookworm vaccine NA-APR-1

License and collaboration between Arrowhead and Amgen closed

Spectrum Pharmaceuticals receives CRL from FDA on Qapzola

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....